Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors

Conditions

• Advanced Malignant Solid Neoplasm
• Refractory Malignant Solid Neoplasm

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Cabozantinib — DRUG
  Given PO
• Pamiparib — DRUG
  Given PO

Study Details

This phase I trial finds the best dose and side effects of cabozantinib and pamiparib in treating patients with solid tumors that have spread to other places in the body (advanced) or does not respond to treatment (refractory). Cabozantinib and pamiparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Key Dates

Start date

Feb 9, 2022

Status verified

May 2025

Primary completion

May 5, 2026

Completion

May 5, 2026

Study Design

Enrollment

44 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Treatment (cabozantinib, pamiparib)
  Patients receive cabozantinib PO QD and pamiparib PO BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Incidence of adverse events [ Time Frame: Up to 6 months ]

Locations (1)

Find similar trials in Houston, TX

Related Studies

• Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
  PHASE1 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas
• Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
  PHASE1/PHASE2 · Recruiting · Children's Oncology Group · Birmingham, Alabama
• CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
  PHASE1/PHASE2 · Recruiting · Children's Oncology Group · Birmingham, Alabama
• Adoption of Audio Recording in the Outpatient Supportive Care Center
  Not Yet Recruiting · M.D. Anderson Cancer Center · Houston, Texas